Biocon and Voluntis deal to transform insulin biosimilars personalized care through digital therapeutics
Biocon and Voluntis deal to transform insulin biosimilars personalized care through digital therapeutics: Biocon Biologics India, a subsidiary of Biocon, and digital therapeutics company Voluntis have recently announced a global collaboration agreement between Biocon Biologics’ subsidiary Biocon Sdn. Bhd.
VARINDIA- INDIA'S FRONTLINE IT MAGAZINE
VARINDIA- INDIA'S FRONTLINE IT MAGAZINE
Comments
Post a Comment